ContraFect (CFRX) to Present New Data from CF-301 Study at ECCMID – StreetInsider.com

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces the presentation of new data from its Phase 1 CF-301 study at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) to be held on April 22-25, 2017 in Vienna, Austria.

ContraFect's lead compound, CF-301 is a first-in-class lysin which has demonstrated a rapid and potent ability to kill Staphylococcus aureus (Staph aureus) bacteria in vitro and in animal studies. CF-301 is currently in development for the treatment of bacteremia due to Staph aureus, including methicillin resistant strains (MRSA). Initial results from the Phase 1, first-in-human study of CF-301 in healthy volunteers, which were presented in a late breaker presentation at ECCMID 2016, showed CF-301 to be well-tolerated with no clinical adverse safety signals. This year, long term follow-up data from this Phase 1 trial will be presented at ECCMID. In addition, a newly developed methodology for testing the susceptibility of Staph aureus bacteria to CF-301 in clinical settings will be presented.

"We are pleased to return to ECCMID, where we will present additional six-month follow up results from the initial Phase 1 study which extend our understanding of the safety profile of CF-301 and the timeframe for the resolution of anti-drug antibodies. We are also presenting a new methodology for CF-301 susceptibility testing, which has been optimized for use in clinical testing laboratories and which will be used in our upcoming Phase 2 study," said Cara Cassino, M.D., EVP of Research and Development and Chief Medical Officer at ContraFect.

Presentation Details:

Presentation Title: Long-Term Immunology Follow-up Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of Intravenous Doses of CF-301 In Human Subjects Session Day & Time: Saturday, April 22, 2017, 3:30p - 4:30p CET (10:30a-11:30a ET) Abstract Number: 7121 Session Title: Phages and Phage Products

Presentation Title: Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301 Session Day & Time: Saturday, April 22, 2017, 08:45a - 3:30p CET (3:45a-10:30a ET) E-poster number: EV0038 Abstract Number: 6193 Session Title: Bacterial Susceptibility & Resistance

The abstracts can be accessed through the ECCMID website. Following the meeting, the presentation posters will be available on the ContraFect Corporation website.

Continue reading here:

ContraFect (CFRX) to Present New Data from CF-301 Study at ECCMID - StreetInsider.com